Terrific debate featuring Drs Virginia Borges and Martine Piccart on the role of anthracyclines in early breast cancer. This summary from Dr Piccart captures much of the final recommendation
Big news: approval in the altered population only. Great to have this new option! @OncoAlert FDA approves capivasertib with fulvestrant for breast cancer | FDA https://t.co/J6msOP5x84
Oof. 😓 Burnout among oncologists has increased from 34% to 59% over the past 10 years. 22% likely to reduce clinical hours in the next year (up from 16%). #ASCOQLTY23
Assessment of use and impact of chemotherapy in T1aN0 TNBC
1,739 pts (SEER Database)
📌Adjuvant chemotherapy is not associated with benefit on OS (HR, 0.63; 95% CI, 0.35-1.13) or BCSS (HR, 0.95; 95% CI, 0.37-2.43)
(CI too wide!)
@CBCjournal
https://t.co/wZDsw1U3QK
D-TORCH Study: Topical 1% diclofenac ⬇️ incidence of grade 2+ & all grade hand-foot syndrome. #ASCO23 so devilishly simple, easy to implement & a treatment that doesn’t bust the 🐷bank. What’s not to like?
The KM curve everyone’s been waiting for. Adjuvant ribociclib for 3 years significantly improved iDFS in patients with stage II-III HR+ BC, with 25% reduction in the risk of recurrence & a 3-year iDFS delta of 3.3%. #ASCO23
📣📣📣Amazing results of the addition of Dostarlimab to chemotherapy in first line endometrial cancer. 🔥for dMMR/MSI-H @myESMO#ESMOVirtualPlenary
https://t.co/KkLqtSzDcy